Latest news and opinions from the EASD, e-Learning and the diabetes community

Unusual forms of diabetes

Personalised treatment for people with diabetes is a long-cherished goal of diabetes care. A session on unusual forms of diabetes at the EASD’s Annual Meeting was a timely reminder of just why understanding the differences between people with diabetes is so important.

Trial results support latest ADA/EASD guidelines on role of SGLT-2 inhibitors in managing type 2 diabetes

New trial results announced at the EASD’s recent Annual Meeting, provide fresh evidence in support of joint ADA/EASD guidelines on type 2 diabetes management – specifically, the emphasis on use of SGLT-2 inhibitors in patients at high risk of cardiovascular and kidney complications. Patients with diabetes who have heart failure and reduced ejection fraction are […]

We are what we don’t eat: fasting and diabetes

Intermittent fasting is the diet industry’s hot new kid on the block, dominating headlines and bestseller lists. But for all the books and column inches, evidence of its benefits from clinical trials - particularly human trials – is in relatively short supply. Which made the presentations at the ‘Fasting and diabetes’ session at the EASD’s Annual Meeting especially welcome.

Diabetes in primary care

Primary care was prominent at this year’s EASD Annual Meeting, testament to the “vital, pivotal role played by primary care in diabetes around the world” – as described by Professor Andrew Boulton, chair of the ‘Diabetes in primary care’ session.

Unlocking the potential of digital health

Digital health has been much talked about as one of the great hopes of better diabetes management, and with so many new technologies now established in the market – continuous or flash glucose monitoring (CGM or FGM) in particular, as well as remote data-gathering platforms – the supply side of that expectation seems to be […]

New treatments for NAFLD – Hope or hype?

Non-alcohol related fatty liver disease (NAFLD) is big news these days; already, a quarter of adults in the USA are estimated to have the condition, and prevalence looks set to rise globally in step with the obesity pandemic.

The 56th EASD Annual Meeting − Day 1

Virtual conference. EASD blog – Day 1 (22 September) For obvious reasons, this year’s Annual Meeting was a virtual affair. Which meant that instead of the usual crush of researchers and healthcare professionals, the EASD plaza was populated by surprisingly slender avatars and everyone got a front-row seat at the lectures – albeit via their […]

The 13th International Conference on Advanced Technologies and Treatments for Diabetes - Day 3

Madrid EASD blog – Day 3 (22nd February 2020) The last day of the ATTD conference in Madrid ended, for me, with three very different sessions − from liver disease and hypoglycaemia to metabolic surgery and stem cells.  The increasing burden of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is one being felt […]

The 13th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) - Day 2

Madrid EASD blog – Day 2 (21st February 2020) On the second day of the ATTD conference and, indeed, scattered throughout the programme, were several sessions on the use of SGLT-2 inhibitors in type 1 diabetes. This new class of drug has and is continuing to prove very beneficial in the management of type 2 […]

The 13th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) - Day 1

Madrid EASD blog – Day 1 (20th February 2020) This year’s Advanced Technologies and Treatments for Diabetes (ATTD) conference was held in Madrid in Spain. Over the course of three days, although a much smaller conference than, for example, the congresses of the American Diabetes Association (ADA) and the European Association for the Study of […]

Day 5 at American Diabetes Association annual conference 2019

The last day of this year’s American Diabetes Association (ADA) conference in San Francisco is only a half day – but it is quite a half day! The results from three clinical trials are reporting. Normally on the last day of any conference, attendance has shrunk dramatically. But not today and I enter into a […]

Day 4 at American Diabetes Association annual conference 2019

The penultimate day of the ADA conference starts with the Outstanding Scientific  Achievement Award Lecture given, this year by Professor Sadaf Farooqi from the University of Cambridge. Entitled “Obesity and the Biology of Weight Regulation”, Professor Farooqi’s research focusses on severe obesity and people with this have the highest burden of complications. Deaths from diabetes […]

Day 3 at American Diabetes Association annual conference 2019

My third day in San Francisco starts with a session on “The Resilient Beta Cell in Type 2 Diabetes”. Emerging research is indicating that not all beta cells are equal and that some have very different levels of activity. Professor Jim Johnston from the University of British Columbia in Canada explains that individual beta bells […]

Day 2 at American Diabetes Association annual conference 2019

This year’s organising committee has opted to pepper the 2019 programme with debates and, like yesterday’s debate between Professor David Matthews and Professor Thomas Pieber on the link between hypoglycaemia and cardiovascular events (click here to read the report from Day 1 of the conference), today presents three very different debates. The first of these […]

Day 1 at American Diabetes Association annual conference 2019

This year’s American Diabetes Association 79th Scientific Sessions are being held in San Francisco on the Californian coast. Thousands of delegates from around the world are gathering here for more than 180 sessions and over 2,000 original research presentations. Obviously, I cannot go to all of them – at any one time there are up […]